Skip to content

Randomized comparative clinical trial of diquafosol sodium and Rebamipide eye drops for VDT-related dry eye patients

Randomized comparative clinical trial of diquafosol sodium and Rebamipide eye drops for VDT-related dry eye patients - Comparative study for the efficacy of two eye drops in VDT-related dry eye

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000012742
Enrollment
80
Registered
2014-01-01
Start date
2014-01-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

VDT-related dry eye

Interventions

3% diauafosol sodium eye drops 6 times a day 2% rebamipide eye drops 4 times a day

Sponsors

Department of Ophthalmology, Tokyo Dental College Ichikawa General Hospital
Lead Sponsor
Shimazaki Eye Clinic, Ichikawa Shapo Eye Clinic, Iidabashi Eye Clinic, Shinjuku Eye Clinic, Ryogoku Eye Clinic, Smile Eye Clinic
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Daily VDT workers (>4 hours a day in average) 2) "definite dry eye" or "dry eye suspects" according to the Japanese dry eye criteria in 2006 3) More than mild subjective symptom score by DEQS (dry eye-related quality of life score) 4) No dry eye eye drops for the last 2 weeks or stably used for more than 2 weeks

Exclusion criteria

Exclusion criteria: 1) Daily contact lens user 2) History of diquafosol or rebamipide uses in the last 1 month prior to the initiation of the study 3) Anatomical or functional abnormalities in the eye (ex. lid closure abnormality) 4) History of ophthalmic surgeries for the last 3 months 5) History of lacrimal punctal plug or occlusion 6) Allergy to diauafosal or rebamipide 7) Other conditions that may influence of the assessment of the study

Design outcomes

Primary

MeasureTime frame
1 Changes in symptom scores at 4th week 2 Changes in tear-film break-up time (BUT) at 4th week 3 Changes in maximum opening time (MOT) at 4th week

Secondary

MeasureTime frame
1 Changes in MOT-BUT difference at 4th week 2 Changes in corneal and conjunctival epithelial damage scores at 4th week 3 Changes in subjective scores, BUT, MOT, BUT-MOT difference, and epithelial damage scores at 2nd and 8th weeks 4 Questionnaire

Countries

Japan

Contacts

Public ContactJun Shimazaki

Tokyo Dental College Ichikawa General Hospital Department of Ophthalmology

jun@eyebank.or.jp047-322-0151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026